Release Date: December 17, 2025
Expiration Date: December 17, 2026
Activity Overview
The treatment of gastroesophageal adenocarcinoma (GEA) has undergone significant transformation as novel targeted and immunotherapies have been developed. In particular, multiple treatment approaches are now available for the management of HER2-positive disease across the treatment continuum for metastatic disease, with new therapeutic options poised to join the therapeutic arsenal.
This podcast features a discussion of management of toxicities associated with currently available and emerging treatment approaches for HER2-positive GEA, led by Rohit Gosain, MD; and Rahul Gosain, MD, and featuring 2 faculty experts focused on the management of these tumors.
Target Audience
This educational activity is directed toward US and global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with GEA and BTC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review common and severe adverse events associated with HER2-targeting therapies and analyze trial data to understand mitigation strategies for relevant AEs
- Develop practical approaches to patient education, early AE recognition, and supportive care, emphasizing multidisciplinary collaboration to optimize outcomes and adherence to HER2-targeted therapies being evaluated for GEA
Rahul Gosain, MD, MBA
Medical Director of Wilmot Cancer Institute at Webster
Director of Wilmot Cancer Institute Regional Infusion Services
Assistant Professor of Clinical Medicine
Wilmot Cancer Institute‒University of Rochester
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rohit Gosain, MD
Director of Roswell Park Care Network Southtowns
Assistant Professor of Clinical Medicine
Roswell Park Comprehensive Cancer Center‒University at Buffalo
Rochester, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Geoffery Ku, MD
Associate Attending Physician
Gastrointestinal Oncology and Cellular Therapy Services,
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astellas, AstraZeneca, Bayer, BeOne, BMS, Daiichi Sankyo, Gilead, I-MAB, Jazz, Merck, Oncolys, Pieris, Zymeworks; Grant/Research Funding: AstraZeneca, BMS, CARsgen, Daiichi Sankyo, I-MAB, Jazz, Merck, Oncolys, Triumvira, Zymeworks; Travel Reimbursement: Dava Oncology, I-MAB
Shruti Patel, MD
Staff Oncologist
Department of Medicine
VA Palo Alto
Medical Oncologist
Gastrointestinal Cancer
Clinical Assistant Professor
Stanford University
Palo Alto, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Foundation Medicine, Jazz Pharmaceuticals
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COIs for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here